Objective: To investigate the impact of selenium in the treatment of lymphedema of the head and neck region after radiotherapy alone or in combination with surgery. Subjects and Materials: Between June 1996 and June 2001 a total of 36 cancer patients (29 male, 7 female; median age 61 years) were treated with selenium for persistent, extensive or progressive lymphedema of the head and neck region. Twenty had interstitial endolaryngeal edema associated with stridor and dyspnea. All patients received 350 µg/m2 body surface sodium selenite medication p.o. daily (total dose 50 µg per day) for a period of 4–6 weeks after radiotherapy. The optimal effect of the selenium treatment was assessed after 4 weeks of therapy using the Miller score system. A visual analogue scale on a scale of 0–10 was used to assess the patient’s quality of life prior to and after selenium. Results: 75% of the patients had an improvement of the Miller score of one stage or more. The self-assessment of quality of life using the visual analogue scale improved significantly after selenium treatment with a reduction of 4.4 points (p < 0.05). Of the 20 patients with endolaryngeal edema tracheostomy was not necessary in 13 patients (65%), but 5 and 2 received a temporary or permanent tracheostomy, respectively. No episode of erysipelas was observed in all study patients. Conclusion: Our results suggest a short positive effect of sodium selenite on secondary head and neck lymphedema caused by radiotherapy alone or in combination with surgery.
© 2004 S. Karger AG, Basel
- Sodium selenite
- Glutathione peroxidase
- Head and neck cancer
- Endolaryngeal edema
- Petrek JA, Pressman PI, Smith RA: Lymphedema: Current issues in research and management. CA Cancer J Clin 2000;50:292–307.
- Rockson SG: Lymphedema. Am J Med 2001;110:288–295.
- Weissleder H, Schuchardt C: Lymphedema of the arm following breast cancer therapy; in Weissleder H, Schuchardt C (eds): Lymphedema: Diagnosis and Therapy, ed 3. Cologne, Viavital, 2001, pp 187–213.
- Weissleder H, Schuchardt C: Iatrogenic alteration of the lymphatic system; in Weissleder H, Schuchardt C (eds): Lymphedema: Diagnosis and Therapy, ed 3. Cologne, Viavital, 2001, pp 156–174.
- Paskett ED, Stark N: Lymphedema: Knowledge, Treatment, and Impact among Breast Cancer Survivors. Breast J 2000;6:373–378.
- Megens A, Harris SR: Physical therapist management of lymphedema following treatment for breast cancer: A critical review of its effectiveness. Phys Ther 1998;78:1302–1311.
- Földi E: The treatment of lymphedema. Cancer 1998;83:2833–2834.
- Kasseroller RG, Schrauzer GN: Treatment of secondary lymphedema of the arm with physical decongestive therapy and sodium selenite: A review. Am J Ther 2000;7:273–279.
- Bruns F, Micke O, Bremer M: Current status of selenium and other treatments for secondary lymphedema. J Support Oncol 2003;1:121–138.
- Casley-Smith JR: Benzo-pyrones in the treatment of lymphoedema. Int Angiol 1999;18:31–41.
- Piller NB: Macrophage and tissue changes in the developmental phases of secondary lymphoedema and during conservative therapy with benzopyrone. Arch Histol Cytol 1990;53:209–218.
- Casley-Smith JR, Gaffney RM: Excess plasma proteins as a cause of chronic inflammation and lymphodema: Quantitative electron microscopy. J Pathol 1981;133:243–272.
- Casley-Smith JR, Morgan RG, Piller NB: Treatment of lymphedema of the arms and legs with 5,6-benzo-[alpha]-pyrone. N Engl J Med 1993;329:1158–1163.
- Loprinzi CL, Sloan J, Kugler J: Coumarin-induced hepatotoxicity. JCO 1997;15:3167–3168.
- Schuchardt C, Pritschow H, Weissleder H: Conservative treatment; in Weissleder H, Schuchardt C (eds): Lymphedema: Diagnosis and Therapy, ed 3. Cologne, Viavital, 2001, pp 336–358.
- Schünemann H, Willich N: Lymphoedema of the arm after treatment of cancer of the breast: A study of 5868 cases. Dtsch Med Wochenschr 1997;122:536–541.
- Walley DR, Augustine E, Saslow D, Bailey S, Jeffs E, Lasinski B, Plotkin J, Walker M: American Cancer Society Lymphedema Workshop. Workgroup IV: Lymphedema treatment resources-professional education and availability of patient services. Cancer 1998;83:2886–2887.
- Rockson SG, Miller LT, Senie R, Brennan MJ, Casley-Smith JR, Földi E, Földi M, Gamble GL, Kasseroller RG, Leduc A, Lerner R, Mortimer PS, Norman SA, Plotkin CL, Rinehart-Ayres ME, Walder AL: American Cancer Society Lymphedema Workshop. Workgroup III: Diagnosis and management of lymphedema. Cancer 1998;83:2882–2885.
- Ewald H: Radiotherapy of head and neck tumours and risk of lymphedema (in German). Z Lymphol 1996;20:21–26
- Micke O, Bruns F, Schäfer U, Kisters K, Hesselmann S, Willich N: Selenium in the treatment of acute and chronic lymphedema. Trace Elem Electrolytes 2000;17:206–209.
- Brenke R, Siems W: Adjuvant therapy in lymphedema. Z Lymphol 1996;20:31–35.
- Kasseroller R: Sodium selenite as prophylaxis against erysipelas in secondary lymphedema. Anticancer Res 1998;18:2227–2230.
- Beier A, Siems W, Brenke R, Grune T: Increased formation of free radicals in chronic lymphedema. Z Lymphol 1994;18:8–11.
- Dietz A, Rudat V, Nollert J, Helbig M, Vanselow B, Weidauer H: Chronic laryngeal edema as a late reaction to radiochemotherapy. HNO 1998;46:731–738.
- Rubin P, Constine LS, Fajardo LF, Phillips TL, Wasserman TH: RTOG Late Effects Working Group. Overview. Late Effects on Normal Tissues (LENT) scoring system. Int J Radiat Oncol Biol Phys 1995;31:1041–1042.
- Földi E: Treatment of lymphedema and patient rehabilitation. Anticancer Res 1998;18:2211–2212.
- Miller AJ, Bruna J, Beninson J: A universally applicable clinical classification of lymphedema. Angiology 1999;50:189–192.
- Herpertz U: Measuring and documentation of edema. Z Lymphol 1994;18:24–30.
- Johnson EW: Visual analog scale (VAS). Am J Phys Med Rehabil 2001;80:717.
- Obenheimer H, Jankowiak P, Berlemann K, Hermann V, Diethelm A: Clinical and biological effects of selenium in edema; in Gonzalez G (ed): Lymphedema: New Perspectives in Research and Treatment. Zaragossa, 1976.
- Peters GM, Herbert WD: Reduction of edema in brain tumors by selenium application. Acta Neurol Pathol Oncol 1957;11:351–353.
- Whanger PD: Selenoprotein W: A review. Cell Mol Life Sci 2000;57:1846–1852.
- Rayman MP: The importance of selenium to human health. Lancet 2000;356:233–241.
- Mücke R, Micke O, Schönekaes KG: Serum selenium levels, glutathione peroxidase activities and serum redox potential levels in patients with untreated non-small cell lung cancer and adenocarcinoma of the rectum. Trace Elem Electrolytes 2003;20:148.
- Miller S, Walker SW, Arthur JR, Nicol F, Pickard K, Lewin MH, Howie AF, Beckett GJ: Selenite protects human endothelial cells from oxidative damage and induces thioredoxin reductase. Clin Sci (Lond) 2001;100:543–550.
- Bahadur S, Amatya RC, Kacker SK: The enigma of post-radiation oedema and residual or recurrent carcinoma of the larynx and pyriform fossa. J Laryngol Otol 1985;99:763–765.
- Horvathova M, Jahnova E, Gazdik F: Effect of selenium supplementation in asthmatic subjects on the expression of endothelial cell adhesion molecules in culture. Biol Trace Elem Res 1999;69:15–26.
- Kiremidjian-Schumacher L, Roy M, Glickman R, Schneider K, Rothstein S, Cooper J, Hochster H, Kim M, Newman R: Selenium and immunocompetence in patients with head and neck cancer. Biol Trace Elem Res 2000;73:97–111.
Dr. Oliver Micke
Klinik und Poliklinik für Strahlentherapie-Radioonkologie
Universitätsklinikum Münster, Albert-Schweitzer-Strasse 33
DE–48129 Münster (Germany)
Tel. +49 251 8347839, Fax +49 251 8347355, E-Mail firstname.lastname@example.org
Received: August 3, 2002
Revised: August 25, 2003
Number of Print Pages : 6
Number of Figures : 1, Number of Tables : 3, Number of References : 38
Medical Principles and Practice
A Publication of the Academic Publications Council
Vol. 13, No. 4, Year 2004 (Cover Date: July-August 2004)
Journal Editor: Farida Al Awadi, Kuwait
ISSN: 1011–7571 (print), 1423–0151 (Online)
For additional information: http://www.karger.com/mpp
Open Access License / Drug Dosage / Disclaimer
Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license
), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.